This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

DBT and Escitalopram in Borderline Personality Disorder

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2005 by Bronx VA Medical Center.
Recruitment status was:  Recruiting
Information provided by:
Bronx VA Medical Center Identifier:
First received: November 17, 2005
Last updated: NA
Last verified: November 2005
History: No changes posted
Subjects will receive six months of DBT, consisting of one 90-minute group and one 60-minute individual session per week as well as telephone availability of the individual therapist. Half the subjects will concurrently receive escitalopram while half will receive placebo, in a randomized double-blind design.

Condition Intervention
Borderline Personality Disorder Behavioral: Dialectical Behavioral Therapy Drug: Escitalopram

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Effects of Dialectical Behavioral Therapy and Escitalopram on Impulsive Aggression, Affective Instability and Cognitive Processing in Borderline Personality Disorder

Resource links provided by NLM:

Further study details as provided by Bronx VA Medical Center:

Primary Outcome Measures:
  • Measures of impulsivity, aggression, affective impulsivity, immediate and delayed memory, and cognitive processing at baseline, 6 months and 9 months


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria: Is a male or female between 18 and 60 who meets criteria for Borderline Personality Disorder and has been off psychotropic medications for at least 2 weeks (6 weeks for fluoxetine).

Exclusion Criteria: Meets criteria for Schizophrenia, Bipolar Disorder, Mental Retardation, current or recent Substance Dependence or a current Major Depressive Episode. Subjects also should not currently be in individual psychotherapy. (Case management and work therapy programs are allowed.)

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00255554

Contact: Emily Hart 212-241-0441

United States, New York
Bronx VA Medical Center Recruiting
Bronx, New York, United States, 10029
Sponsors and Collaborators
Bronx VA Medical Center
Principal Investigator: Marianne Goodman, MD Bronx VA Medical Center/Mount Sinai School of Medicine
  More Information Identifier: NCT00255554     History of Changes
Other Study ID Numbers: 3277-03-0027
Study First Received: November 17, 2005
Last Updated: November 17, 2005

Keywords provided by Bronx VA Medical Center:
Borderline Personality Disorder
Dialectical Behavior Therapy

Additional relevant MeSH terms:
Personality Disorders
Borderline Personality Disorder
Pathologic Processes
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents processed this record on September 20, 2017